HCM - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 | Benzinga
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology ("ESMO") Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.
Details of the presentations are as follows:
| Abstract title |
| Presenter / Lead author |
| Presentation details |
SPONSORED STUDY |
| Fruquintinib plus Sintilimab in patients with either treatment naïve or previously treated advanced gastric or gastroesophageal junction adenocarcinoma: results from a multicenter, single-arm phase Ib/II study |
| Xiaoli Wei, Harbin Medical University Cancer Hospital, Harbin, China |
| 1519P Poster presentation (Oesophagogastric cancer) Monday, October 23, 2023 |
INVESTIGATOR-INITIATED STUDIES |
| First report of the safety/tolerability and preliminary antitumor activity of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer: an open-label, randomized phase Ib/II study |
| Wenhua Li, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China |
| 639P Poster presentation (Colorectal cancer) Sunday, October 22, 2023 |